Novel HIV-1 glycoprotein vaccines with enhanced presentation of broad neutralization epitopes

新型 HIV-1 糖蛋白疫苗，具有增强的广泛中和表位呈现

• 批准号: nhmrc : 1125822
• 负责人: A/Pr Heidi Drummer
• 金额: $ 50.76万
• 依托单位: Macfarlane Burnet Institute for Medical Research and Public Health
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-hiv-1-neutralization-epitopes/947680
• 关键词: Novel; HIV; glycoprotein; vaccines; enhanced

A prophylactic vaccine represents the best strategy for blocking HIV-1 transmission but one is not yet available. Current antiviral vaccines rely on neutralizing antibodies (NAbs) that block infection, however, current HIV-1 vaccine formulations do not induce broadly reactive NAbs (bNAbs). We have discovered a novel HIV-1 glycoprotein vaccination candidate with enhanced presentation of bNAb epitopes. We propose to determine if this vaccine induces effective bNAbs in experimental animals.

预防性疫苗是阻断HIV-1传播的最佳策略，但目前还没有。目前的抗病毒疫苗依赖于阻断感染的中和抗体（NAb），然而，目前的HIV-1疫苗制剂不诱导广泛反应性NAb（bNAb）。我们发现了一种新的HIV-1糖蛋白疫苗候选物，其具有增强的bNAb表位呈递。我们建议确定该疫苗是否在实验动物中诱导有效的bNAb。